Manuel Ayala

1.7k total citations · 1 hit paper
10 papers, 1.2k citations indexed

About

Manuel Ayala is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Manuel Ayala has authored 10 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Genetics and 8 papers in Rheumatology. Recurrent topics in Manuel Ayala's work include Chronic Myeloid Leukemia Treatments (10 papers), Eosinophilic Disorders and Syndromes (8 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Manuel Ayala is often cited by papers focused on Chronic Myeloid Leukemia Treatments (10 papers), Eosinophilic Disorders and Syndromes (8 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Manuel Ayala collaborates with scholars based in Mexico, Germany and Argentina. Manuel Ayala's co-authors include Jörge E. Cortes, Sandip Shah, Michele Baccarani, M. Brigid Bradley‐Garelik, Chao Zhu, Andreas Hochhaus, Beatriz Moiraghi, Hagop M. Kantarjian, Eric Bleickardt and Charles Chuah and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Manuel Ayala

9 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2010 1.1k citations Hagop M. Kantarjian, Neil P. Shah et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuel Ayala Mexico	4	1.0k	854	548	172	133	10	1.2k
Jorge Milone Argentina	10	977 1.0×	833 1.0×	577 1.1×	158 0.9×	98 0.7×	30	1.1k
Agnès Guerci‐Bresler France	18	1.4k 1.3×	1.1k 1.3×	546 1.0×	237 1.4×	111 0.8×	53	1.5k
Jenny Shan United States	13	1.2k 1.1×	923 1.1×	608 1.1×	121 0.7×	149 1.1×	26	1.3k
Franck E. Nicolini France	19	1.5k 1.4×	1.2k 1.4×	697 1.3×	253 1.5×	209 1.6×	64	1.7k
Н Д Хорошко Russia	8	767 0.7×	651 0.8×	511 0.9×	126 0.7×	77 0.6×	13	883
Laurie Letvak United States	14	749 0.7×	566 0.7×	514 0.9×	144 0.8×	121 0.9×	31	981
Benjamin Hanfstein Germany	11	983 1.0×	784 0.9×	562 1.0×	139 0.8×	114 0.9×	28	1.1k
Bruno Villemagne France	8	569 0.6×	510 0.6×	259 0.5×	135 0.8×	54 0.4×	12	639
Jean Michel Cayuela France	10	481 0.5×	411 0.5×	245 0.4×	149 0.9×	54 0.4×	12	727
Marianne Rosamilia United States	5	483 0.5×	309 0.4×	215 0.4×	119 0.7×	93 0.7×	7	684

Countries citing papers authored by Manuel Ayala

Since Specialization

Citations

This map shows the geographic impact of Manuel Ayala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Ayala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Ayala more than expected).

Fields of papers citing papers by Manuel Ayala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Ayala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Ayala. The network helps show where Manuel Ayala may publish in the future.

Co-authorship network of co-authors of Manuel Ayala

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Ayala. A scholar is included among the top collaborators of Manuel Ayala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Ayala. Manuel Ayala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Cortes, Jörge E., Cármino Antônio De Souza, Manuel Ayala, et al.. (2016). Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. The Lancet Haematology. 3(12). e581–e591. 26 indexed citations

2.

Ayala, Manuel, et al.. (2016). Nilotinib As Second or Third-Line Therapy for Myeloid Chronic Leukemia Chronic-Phase in Mexican Patients. Blood. 128(22). 5459–5459. 3 indexed citations

3.

Ayala, Manuel, et al.. (2016). Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia. Blood. 128(22). 5430–5430. 1 indexed citations

4.

Ayala, Manuel, et al.. (2015). Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at “La Raza” Medical Center in Mexico. Clinical Lymphoma Myeloma & Leukemia. 16(2). 57–62. 3 indexed citations

5.

Cortes, Jörge E., Cármino Antônio De Souza, José López, et al.. (2013). Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial. Blood. 122(21). 95–95. 7 indexed citations

6.

Meillón, Luis, et al.. (2012). Molecular Status Evaluation in a Standardized Laboratory in a Cohort of Patients with Chronic Myeloid Leukemia At the Instituto Mexicano Del Seguro Social (IMSS). Blood. 120(21). 4452–4452. 1 indexed citations

7.

Kantarjian, Hagop M., Neil P. Shah, Andreas Hochhaus, et al.. (2010). Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine. 362(24). 2260–2270. 1103 indexed citations breakdown →

8.

Baccarani, Michele, Jörge E. Cortes, Manuel Ayala, et al.. (2010). Dasatinib compared to imatinib in patients with newly diagnosedchronic-phase chronic myelogenous leukemia (CML-CP): resultsfrom the randomized phase 3 dasision tria. 1 indexed citations

9.

Kantarjian, Hagop M., Neha Shah, Andreas Hochhaus, et al.. (2010). Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.. Journal of Clinical Oncology. 28(18_suppl). LBA6500–LBA6500. 10 indexed citations

10.

Ayala, Manuel, et al.. (2007). Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.. Blood. 110(11). 4578–4578.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact